You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Journal logo
Sections
Ask the Ethicist
At the Bench
Best Advances
Disease Mechanisms
Diversity
For Your Patients
In the Pipeline
Off the Clock
Neurotech
Letters to the Editor
Policy and Practice
Professionalism
The Science Explained
Wellness
Topics
Behavioral Neurology/Dementia
Cerebrovascular Disease
Child Neurology
Epilepsy
Genetics
Headache/Facial Pain
Movement Disorders
Multiple Sclerosis
Neurocritical Care
Neuroinfectious Disease
Neuromuscular
Neuro-oncology
Neuro-ophthalmology/Neuro-otology
Sleep Neurology
Sports Neurology/Concussion
At the Meetings
Meetings We Cover
Most Recent Meeting
About
About Neurology Today
Editorial Board
Subscription Services
Reprints
Rights and Permissions
About the AAN
American Academy of Neurology
Account
Register
Help
American Academy of Neurology
Login
Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy.
Subscribe to eTOC
Home
>
Issue Outline
November 03, 2011
Volume 11, Issue 21
Browse Issues
For Your Patients
For Your Patients
FDA Committee: Rasagiline Rejected as ‘Disease Modifying’ for Parkinson Disease
For Your Patients
Investigators Restore Working Memory in Aged Monkeys
For Your Patients
At Unique ALS Meeting, New Discoveries, Paradigms, and Complexities Are Front and Center
For Your Patients
IOM: Data Lacking on Benefits of Cognitive Therapy for Traumatic Brain Injury
For Your Patients
A New Oral Drug for MS: How Does it Compare?
For Your Patients
Alpha-synuclein Induces Lewy Body Formation and Neuronal Death, Supporting Cell-to-Cell Disease Transmission A New Model for Parkinson Disease?
For Your Patients
News from the ANA Annual Meeting: MS Death Rate Lower with Early Interferon Use, Study Shows
For Your Patients
Adjunct AEDS Cut Sudden Death Risk Seven-Fold in Drug-Resistant Epilepsy
For Your Patients
How Do Epilepsy Patients Fare in the Long-term After Surgery?
For Your Patients
FDA Approves Clobazam for Reducing Lennox-Gastaut Seizures
For Your Patients
News from ECTRIMS/ACTRIMS Fifth Triennial Conference: MS Drugs Take Center Stage at ECTRIMS/ACTRIM: Weighing their Pros and Cons
For Your Patients
New Molecular DNA Test May Help Detect Down Syndrome
For Your Patients
Young Neurologists Express Career Regret
For Your Patients
Meeting Planner
For Your Patients
Policy Watch: Will a New Reimbursement Model be Coming to Your Area? Massachusetts Program Gains Traction
Issue Cover
Editor's Pick Podcast
Back to Top